Literature DB >> 18196237

Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease.

Karl Herholz1.   

Abstract

PURPOSE: Impairment of cholinergic neurotransmission is a well-established fact in Alzheimer's disease (AD), but there is controversy about its relevance at the early stages of the disease and in mild cognitive impairment (MCI).
METHODS: In vivo positron emission tomography imaging of cortical acetylcholine esterase (AChE) activity as a marker of cholinergic innervation that is expressed by cholinergic axons and cholinoceptive neurons has demonstrated a reduction of this enzyme activity in manifest AD. The technique is also useful to measure the inhibition of cerebral AChE induced by cholinesterase inhibitors for treatment of dementia symptoms.
RESULTS: A reduction of cortical AchE activity was found consistently in all studies of AD and in few cases of MCI who later concerted to AD.
CONCLUSION: The in vivo findings in MCI and very mild AD are still preliminary, and studies seem to suggest that cholinergic innervation and AChE as the main degrading enzyme are both reduced, which might result in partial compensation of their effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18196237     DOI: 10.1007/s00259-007-0699-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  42 in total

1.  Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease.

Authors:  J O Rinne; V Kaasinen; T Järvenpää; K Någren; A Roivainen; M Yu; V Oikonen; T Kurki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

2.  Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease.

Authors:  Carsten Eggers; Karl Herholz; Elke Kalbe; Wolf-Dieter Heiss
Journal:  Neurosci Lett       Date:  2006-09-25       Impact factor: 3.046

3.  Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.

Authors:  Valtteri Kaasinen; Kjell Någren; Tarja Järvenpää; Anne Roivainen; Meixiang Yu; Vesa Oikonen; Timo Kurki; Juha O Rinne
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

Review 4.  Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection.

Authors:  Martin Sarter; Michael E Hasselmo; John P Bruno; Ben Givens
Journal:  Brain Res Brain Res Rev       Date:  2005-02

5.  Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease.

Authors:  M Iyo; H Namba; K Fukushi; H Shinotoh; S Nagatsuka; T Suhara; Y Sudo; K Suzuki; T Irie
Journal:  Lancet       Date:  1997-06-21       Impact factor: 79.321

6.  Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling.

Authors:  S Nagatsuka Si; K Fukushi; H Shinotoh; H Namba; M Iyo; N Tanaka; A Aotsuka; T Ota; S Tanada; T Irie
Journal:  J Cereb Blood Flow Metab       Date:  2001-11       Impact factor: 6.200

7.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

Authors:  Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

8.  Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

Authors:  Nicolaas I Bohnen; Daniel I Kaufer; Larry S Ivanco; Brian Lopresti; Robert A Koeppe; James G Davis; Chester A Mathis; Robert Y Moore; Steven T DeKosky
Journal:  Arch Neurol       Date:  2003-12

Review 9.  Acetylcholinesterase imaging: its use in therapy evaluation and drug design.

Authors:  Hitoshi Shinotoh; Kiyoshi Fukushi; Shin-ichiro Nagatsuka; Toshiaki Irie
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

10.  PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor.

Authors:  B Bencherif; C J Endres; J L Musachio; A Villalobos; J Hilton; U Scheffel; R F Dannals; S Williams; J J Frost
Journal:  Synapse       Date:  2002-07       Impact factor: 2.562

View more
  17 in total

Review 1.  Role of insulin resistance in Alzheimer's disease.

Authors:  Zhiyou Cai; Ming Xiao; Liying Chang; Liang-Jun Yan
Journal:  Metab Brain Dis       Date:  2014-11-16       Impact factor: 3.584

2.  Mixed-effect circadian rhythm model for human erythrocyte acetylcholinesterase activity--application to the proof of concept of cholinesterase inhibition by acorn extract in healthy subjects with galantamine as positive control.

Authors:  Seunghoon Han; Jongtae Lee; Sangil Jeon; Taegon Hong; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2011-12-30       Impact factor: 2.953

3.  Clitoria ternatea ameliorated the intracerebroventricularly injected streptozotocin induced cognitive impairment in rats: behavioral and biochemical evidence.

Authors:  Jogender Mehla; Monika Pahuja; Pooja Gupta; Shekhar Dethe; Amit Agarwal; Yogendra Kumar Gupta
Journal:  Psychopharmacology (Berl)       Date:  2013-07-06       Impact factor: 4.530

Review 4.  The senescence hypothesis of disease progression in Alzheimer disease: an integrated matrix of disease pathways for FAD and SAD.

Authors:  Sally Hunter; Thomas Arendt; Carol Brayne
Journal:  Mol Neurobiol       Date:  2013-04-03       Impact factor: 5.590

5.  Acetylcholinesterase protein level is preserved in the Alzheimer's brain.

Authors:  María-Letizia Campanari; María-Salud García-Ayllón; Lidia Blazquez-Llorca; Wilson K W Luk; Karl Tsim; Javier Sáez-Valero
Journal:  J Mol Neurosci       Date:  2013-12-07       Impact factor: 3.444

Review 6.  Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.

Authors:  Shringika Soni; Rakesh Kumar Ruhela; Bikash Medhi
Journal:  Adv Pharm Bull       Date:  2016-09-25

Review 7.  N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.

Authors:  David Olivares; Varun K Deshpande; Ying Shi; Debomoy K Lahiri; Nigel H Greig; Jack T Rogers; Xudong Huang
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

8.  Anticholinergic drug use and risk for dementia: target for dementia prevention.

Authors:  Frank Jessen; Hanna Kaduszkiewicz; Moritz Daerr; Horst Bickel; Michael Pentzek; Steffi Riedel-Heller; Michael Wagner; Siegfried Weyerer; Birgitt Wiese; Hendrik van den Bussche; Karl Broich; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-10-20       Impact factor: 5.270

9.  Association of β-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.

Authors:  Han Soo Yoo; Seun Jeon; Enrica Cavedo; MinJin Ko; Mijin Yun; Phil Hyu Lee; Young H Sohn; Michel J Grothe; Stefan Teipel; Harald Hampel; Alan C Evans; Byoung Seok Ye
Journal:  Neurology       Date:  2021-12-30       Impact factor: 9.910

10.  Activation of GSK-3 disrupts cholinergic homoeostasis in nucleus basalis of Meynert and frontal cortex of rats.

Authors:  Yue Wang; Qing Tian; En-Jie Liu; Li Zhao; Jie Song; Xin-An Liu; Qing-Guo Ren; Xia Jiang; Juan Zeng; Yu-Tao Yang; Jian-Zhi Wang
Journal:  J Cell Mol Med       Date:  2017-06-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.